At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ORMP Oramed Pharmaceuticals
Closed Mourning Day 01-08 16:00:00 EST
2.38
-0.04
-1.65%
盘后2.38
+0.000.00%
19:40 EST
High2.40
Low2.37
Vol109.93K
Open2.40
D1 Closing2.42
Amplitude1.24%
Mkt Cap95.94M
Tradable Cap80.11M
Total Shares40.31M
T/O261.94K
T/O Rate0.33%
Tradable Shares33.66M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Oramed Pharmaceuticals Inc - On Dec 13, Received $13.2 Million Payment From Scilex, Pursuant To Terms Of Tranche A Note
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.